单位:[1]Division of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China华中科技大学同济医学院附属同济医院内科学系心血管内科[2]Department of Cardiology, China-Japan Friendship Hospital, Beijing, China[3]Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China首都医科大学附属安贞医院[4]Stephenson Cancer Center and Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma, OK, USA
This work was supported by grant from the National Natural Science Foundation of China (Nos. 91439203, 81630010, 31771264, 81700262 and 81600213).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类|2 区医学
小类|2 区肿瘤学3 区细胞生物学
最新[2025]版:
无
第一作者:
第一作者单位:[1]Division of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Yanru Zhao,Mengwen Yan,Chen Chen,et al.MiR-124 aggravates failing hearts by suppressing CD151-facilitated angiogenesis in heart[J].Oncotarget.2018,9(18):14382-14396.doi:10.18632/oncotarget.24205.
APA:
Yanru Zhao,Mengwen Yan,Chen Chen,Wei Gong,Zhongwei Yin...&Houjuan Zuo.(2018).MiR-124 aggravates failing hearts by suppressing CD151-facilitated angiogenesis in heart.Oncotarget,9,(18)
MLA:
Yanru Zhao,et al."MiR-124 aggravates failing hearts by suppressing CD151-facilitated angiogenesis in heart".Oncotarget 9..18(2018):14382-14396